ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AXON Axon Enterprise Inc

300.23
-3.20 (-1.05%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Axon Enterprise Inc NASDAQ:AXON NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.20 -1.05% 300.23 299.50 301.00 305.105 300.048 303.88 507,020 01:00:00

Axovant to Present at First Annual Roivant Pipeline Day

18/06/2018 1:30pm

GlobeNewswire Inc.


Axon Enterprise (NASDAQ:AXON)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Axon Enterprise Charts.

Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET.

A live webcast will be available in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following the conference.

About Roivant Pipeline Day

Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City. The event will feature presentations, fireside chats, and Q&A sessions from executives across the Roivant family of companies. The event is scheduled to begin at 2:00 p.m. ET and will continue until approximately 5:30 p.m. ET. Due to limited capacity, attendance is by invitation only but a live webcast will be available to interested parties. To request access to the webcast or to learn more about the event, please email pipelineday@roivant.com.

About Axovant Sciences

Axovant is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics in the fields of neurology and psychiatry. We are developing a pipeline of clinical and nonclinical product candidates that focuses on the various aspects of debilitating neurodegenerative diseases such as Parkinson’s disease, Alzheimer's disease, Lewy body dementia, and other indications in the fields of neurology and psychiatry. Our goal is to be the leading biopharmaceutical company focused on the fields of neurology and psychiatry.

For more information, visit www.axovant.com.

Contacts:

Investors

Tricia Truehart(631) 892-7014investors@axovant.com

Media

Paul Davis(646) 495-5310media@axovant.com

SOURCE Axovant Sciences

 

1 Year Axon Enterprise Chart

1 Year Axon Enterprise Chart

1 Month Axon Enterprise Chart

1 Month Axon Enterprise Chart

Your Recent History

Delayed Upgrade Clock